(Q47771090)

5 February 2018

title

Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. (English)

1 reference

5 February 2018

author name string

Meredith PA

series ordinal

1

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 1999

1 reference

5 February 2018

Expert Opinion on Investigational Drugs

published in

1 reference

5 February 2018

volume

8

1 reference

5 February 2018

page(s)

1043-1062

1 reference

5 February 2018

issue

7

1 reference

5 February 2018

Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes.

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1043

Oxygen free radical damage of isolated cardiomyocytes: comparative protective effect of radical scavengers and calcium antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1043

Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1043

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1043

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1043

10.1517/13543784.8.7.1043

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

15992105

1 reference

5 February 2018